METHYL AMINOLEVULINATE HYDROCHLORIDE - Generic Drug Details

What are the generic sources for methyl aminolevulinate hydrochloride and what is the scope of patent protection?

Methyl aminolevulinate hydrochloride is the generic ingredient in one branded drug marketed by Galderma Labs Lp and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for METHYL AMINOLEVULINATE HYDROCHLORIDE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	30
DailyMed Link:	METHYL AMINOLEVULINATE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for METHYL AMINOLEVULINATE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Zurich	Early Phase 1
Institut de Cancérologie de Lorraine	Phase 2
University of California, San Francisco	Phase 1

See all METHYL AMINOLEVULINATE HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for METHYL AMINOLEVULINATE HYDROCHLORIDE

L01XD	Sensitizers used in photodynamic/radiation therapy
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for METHYL AMINOLEVULINATE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	METVIXIA	methyl aminolevulinate hydrochloride	CREAM;TOPICAL	021415-001	Jul 27, 2004		DISCN	No	No

Expired US Patents for METHYL AMINOLEVULINATE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	METVIXIA	methyl aminolevulinate hydrochloride	CREAM;TOPICAL	021415-001	Jul 27, 2004

Methyl Aminolevulinate Hydrochloride Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 5, 2026

Methyl aminolevulinate hydrochloride is a topical photodynamic-therapy drug marketed primarily as Metvix or Metvixia. Its commercial value is concentrated in actinic keratosis, superficial basal cell carcinoma, and Bowen disease. The product has an established regulatory and clinical position in Europe and selected international markets, but its growth is constrained by photodynamic-therapy infrastructure, physician training, treatment discomfort, and competition from cryotherapy, topical medicines, surgery, and other photodynamic agents.

The original composition and use patents are no longer the principal commercial barrier in most markets. Current value depends more on brand recognition, regulatory approvals, distributor access, physician familiarity, treatment-center capacity, and ownership of local marketing rights. Standalone revenue is not publicly disclosed by the current commercial owner, making precise market-share and product-level revenue estimates unavailable.

What is methyl aminolevulinate hydrochloride used for?

Methyl aminolevulinate hydrochloride is a topical prodrug used with red or daylight photodynamic therapy. After application to a lesion, the compound is converted through the heme biosynthesis pathway into protoporphyrin IX. Illumination activates protoporphyrin IX and produces reactive oxygen species that damage abnormal cells.

The main indications are:

Indication	Typical commercial role	Market characteristics
Actinic keratosis	Core indication	Large patient population; significant competition from cryotherapy and topical field therapies
Superficial basal cell carcinoma	Important specialist indication	Surgery remains a major comparator; photodynamic therapy is useful for selected lesions
Bowen disease	Niche indication	Smaller addressable population; hospital and dermatology-center use
Other dermatologic lesions	Limited or investigational use	Depends on country-specific approval and reimbursement

The product is supplied as a cream that is applied to the lesion before illumination. Treatment generally requires a dedicated light source and trained personnel. That delivery model differentiates methyl aminolevulinate hydrochloride from self-administered topical therapies.

Which branded products contain methyl aminolevulinate hydrochloride?

The principal branded product is Metvix, also known as Metvixia in some markets. The original development program was associated with Photocure, while commercial rights were transferred or licensed in different territories, including rights associated with Galderma.

Metvix and Metvixia commercial positioning

Metvix has historically been positioned as a dermatologist-administered photodynamic therapy rather than a primary-care or retail product. Its commercial performance depends on:

• Dermatology clinic capacity.
• Access to approved photodynamic light systems.
• Reimbursement for physician-administered treatment.
• The number of eligible lesions treated per session.
• Competition from lower-cost or faster procedures.
• Availability of local marketing authorization holders.

Methyl aminolevulinate hydrochloride should not be confused with aminolevulinic acid hydrochloride, the active ingredient in products such as Ameluz and Levulan. These are related photodynamic agents but are different active pharmaceutical ingredients with separate regulatory and patent histories.

What is the FDA regulatory status of methyl aminolevulinate hydrochloride?

Methyl aminolevulinate hydrochloride does not have the same U.S. regulatory position as aminolevulinic acid hydrochloride. The FDA-approved photodynamic products Ameluz and Levulan contain aminolevulinic acid hydrochloride, not methyl aminolevulinate hydrochloride.[1]

Metvix was approved in Europe for actinic keratosis and selected nonmelanoma skin-cancer indications. The European Medicines Agency describes Metvix as a cream containing methyl aminolevulinate and identifies photodynamic treatment as the associated procedure.[2]

The U.S. commercial consequence is material:

• No established U.S. Metvix franchise comparable to the European business.
• No U.S. Orange Book listing for an FDA-approved methyl aminolevulinate hydrochloride product.
• No U.S. reference-product framework equivalent to the Ameluz or Levulan markets.
• A U.S. entrant would require an FDA approval pathway rather than relying on an established Orange Book generic substitution route.

What is the Orange Book status of methyl aminolevulinate hydrochloride?

Methyl aminolevulinate hydrochloride has no meaningful Orange Book patent-exclusivity position in the United States because the branded product is not established as an FDA-approved U.S. reference product in the manner of Ameluz or Levulan.[1]

This limits the relevance of U.S. Paragraph IV litigation for Metvix itself. A generic company seeking to commercialize a U.S. methyl aminolevulinate product would more likely confront:

1. The need to obtain FDA approval for the drug and photodynamic-use regimen.
2. Clinical and quality requirements for a topical cream.
3. Potential method-of-use or formulation patents that remain active.
4. Manufacturing and light-treatment compatibility requirements.
5. Commercial uncertainty around reimbursement and physician adoption.

The absence of an Orange Book listing does not mean that all intellectual-property risk is absent. It means the conventional abbreviated new drug application and Paragraph IV pathway is not the central U.S. issue for this product.

When does methyl aminolevulinate hydrochloride lose exclusivity?

The core exclusivity period has largely expired in the major European markets. The original product has been commercialized for more than two decades, and the principal commercial rights have shifted from originator development to regional licensing and established-market sales.

Patent and exclusivity timeline

Period	Commercial or legal development
Late 1990s	Clinical and regulatory development of methyl aminolevulinate photodynamic therapy
Early 2000s	European commercialization of Metvix for actinic keratosis and selected skin cancers
2000s	Expansion of physician-administered photodynamic therapy across European dermatology markets
2009-2010 period	Changes in commercial rights and licensing arrangements involving Photocure and Galderma
2010s	Loss of practical composition-of-matter exclusivity in major markets; product remained commercially relevant through brand and channel position
2020s	Mature-market product with value concentrated in local approvals, supply, reimbursement, and treatment infrastructure

Exact patent expiration dates vary by patent family, jurisdiction, supplementary protection certificate, and claim scope. The economic exclusivity associated with the original active ingredient and principal indication is no longer the primary source of value.

What patents protect methyl aminolevulinate hydrochloride?

The historical patent estate generally covered four categories:

1. The use of methyl aminolevulinate in photodynamic treatment.
2. Topical formulations and cream vehicles.
3. Treatment protocols for actinic keratosis and nonmelanoma skin cancer.
4. Combinations involving the drug and a specific illumination regimen.

The key commercial distinction is between active-ingredient patents and later formulation or method-of-use patents. A compound patent can lose force while later patents continue to protect specific formulations, dosing conditions, treatment intervals, lesion types, or light sources.

Formulation patents

Formulation protection can cover:

• Cream composition.
• Concentration of methyl aminolevulinate.
• Stability and storage conditions.
• Vehicle components.
• Packaging that limits light exposure.
• Uniformity of drug distribution.
• Preparation of the cream for clinical use.

Formulation patents are commercially relevant only if they remain in force in the target country and if the competing product cannot design around the claims. For an established topical medicine, manufacturing know-how and regulatory quality data can matter as much as patent duration.

Method-of-use patents

Method patents may cover:

• Treatment of actinic keratosis.
• Treatment of superficial basal cell carcinoma.
• Treatment of Bowen disease.
• Daylight photodynamic therapy.
• Specific illumination timing or fluence.
• Treatment of field lesions rather than isolated lesions.

Method-of-use protection is generally less effective where physicians can prescribe an alternative regimen or use a different illumination protocol. Enforceability depends on claim language, physician behavior, labeling, and the jurisdiction’s rules on induced infringement and medical-use claims.

How strong is the patent estate for methyl aminolevulinate hydrochloride?

The current patent estate is best characterized as moderate to weak for the active ingredient and potentially stronger for selected local formulations or methods.

Patent layer	Current strategic strength
Active ingredient	Low in mature markets because of age and loss of primary exclusivity
Original photodynamic indication	Low to moderate, depending on jurisdiction and remaining claims
Cream formulation	Moderate if claims are narrow and still active
Treatment protocol	Moderate for specific protocols; weaker against clinically distinct regimens
Manufacturing process	Moderate where process controls are difficult to replicate
Brand and regulatory data	Moderate commercial protection despite limited patent exclusivity
Distribution and physician relationships	Often more important than expired composition patents

The product’s defensibility is therefore not equivalent to that of a newly launched small molecule with long-lived composition patents. Its durable advantages are operational: established clinical data, regulatory history, physician familiarity, and access to treatment centers.

Which companies compete with methyl aminolevulinate hydrochloride?

Competition exists at the drug level and at the procedure level.

Direct photodynamic-therapy competitors

Product	Active ingredient	Company or commercial association	Competitive relevance
Metvix/Metvixia	Methyl aminolevulinate hydrochloride	Galderma and regional rights holders	Established European photodynamic-therapy brand
Ameluz	Aminolevulinic acid hydrochloride	Biofrontera	Direct photodynamic competitor in actinic keratosis
Levulan Kerastick	Aminolevulinic acid hydrochloride	DUSA Pharmaceuticals, associated with Sun Pharma	U.S. photodynamic-therapy competitor

Procedure-level competitors

Methyl aminolevulinate competes with:

• Cryotherapy.
• Curettage and electrodesiccation.
• Surgical excision.
• Mohs surgery.
• Imiquimod.
• 5-fluorouracil.
• Diclofenac topical therapy.
• Tirbanibulin.
• Other field-directed actinic-keratosis treatments.

For superficial basal cell carcinoma, surgical excision and curettage remain important alternatives. For actinic keratosis, low-cost office procedures and self-administered topical therapies create price and convenience pressure.

What market dynamics affect methyl aminolevulinate hydrochloride?

The market is mature and procedure-driven rather than prescription-volume-driven.

Dermatology infrastructure limits demand

Methyl aminolevulinate requires a treatment session, lesion preparation, incubation, and illumination. Clinics need the relevant equipment and staff. This creates a capacity ceiling that does not apply to retail topical medicines.

Reimbursement determines treatment volume

A favorable reimbursement system can support photodynamic therapy despite higher procedural complexity. Where payment is low or bundled, physicians may favor faster cryotherapy or topical prescriptions.

Actinic keratosis provides volume

Actinic keratosis is the largest potential indication because patients often have multiple lesions and recurrent field disease. This creates opportunities for repeat treatments. The same feature increases competition from field therapies that can be prescribed for home use.

Superficial basal cell carcinoma supports specialist value

Photodynamic therapy can be useful where cosmetic outcomes matter or where surgery is less attractive. The addressable population is smaller, but treatment value per case can be higher than for routine actinic keratosis.

Daylight photodynamic therapy may improve convenience

Daylight protocols can reduce treatment burden in suitable climates and settings. Their commercial impact depends on regulatory labeling, seasonal conditions, light availability, and physician willingness to adopt the protocol.

What is the financial trajectory of methyl aminolevulinate hydrochloride?

The product has the financial profile of a mature specialty dermatology medicine rather than a high-growth branded pharmaceutical.

Financial driver	Expected effect
Loss of primary patent exclusivity	Reduces pricing power and increases substitution risk
Established clinical use	Supports recurring demand in approved markets
Clinic-based administration	Limits rapid volume expansion
Repeat actinic-keratosis treatment	Provides recurring utilization
Competition from low-cost procedures	Pressures net price
Regional licensing	Can preserve commercial reach but divides economics
Private ownership of major commercial rights	Reduces public revenue transparency
Lack of U.S. franchise scale	Limits global revenue growth

Photocure’s historical development and licensing activity indicate that Metvix was monetized through commercial rights and partnerships rather than through a permanently controlled global sales platform.[3] Galderma is privately held, and public disclosures do not generally isolate Metvix revenue from its broader dermatology portfolio.[4]

A defensible standalone revenue estimate cannot be derived from public company filings. Market reports may publish broad photodynamic-therapy or actinic-keratosis estimates, but those figures do not reliably identify methyl aminolevulinate hydrochloride sales.

Revenue trajectory by phase

• Early phase: revenue growth was driven by initial European approvals and expansion into additional dermatology markets.
• Mature phase: sales became dependent on repeat treatment, reimbursement, and physician utilization.
• Current phase: financial performance is likely stable to declining in mature markets unless supported by new indications, improved daylight protocols, broader geographic access, or stronger clinic adoption.
• Upside case: renewed growth could come from field therapy adoption, expanded access in emerging markets, and improved treatment convenience.
• Downside case: substitution by cryotherapy, home-use topical products, and competing photodynamic agents.

What generic entry risks exist?

Generic or follow-on entry risk is higher in markets where the active ingredient is off patent and the product is not protected by a strong current formulation patent.

The main barriers are:

• Demonstrating topical formulation quality.
• Establishing stability and light-protection characteristics.
• Satisfying local bioequivalence or clinical requirements.
• Securing approval for the associated illumination procedure.
• Obtaining reimbursement.
• Building relationships with dermatology clinics.
• Matching supply reliability for a light-sensitive product.

Generic entry is less straightforward than for a conventional oral tablet because the therapeutic effect depends on both the cream and the illumination process. A lower-priced cream may still struggle to gain share if physicians prefer the established product or if the competing product lacks compatible treatment protocols.

What patent litigation and settlement agreements affect the product?

No major current U.S. Paragraph IV litigation involving an FDA-approved methyl aminolevulinate hydrochloride reference product is identified in the cited regulatory materials. That result is consistent with the absence of a conventional U.S. Orange Book franchise for Metvix.

Historical commercial arrangements are more important than recent patent litigation. Photocure and Galderma-related licensing and rights transfers shaped the product’s geographic commercialization and revenue allocation.[3] The existence, scope, and current status of private settlement agreements are not generally disclosed in public regulatory product records.

What geographic markets matter most?

Europe has historically been the core commercial region because of early approvals and established dermatology use. Market attractiveness varies by:

• National reimbursement.
• Availability of photodynamic light equipment.
• Dermatologist density.
• Skin-cancer screening practices.
• Incidence of actinic damage.
• Local competition from surgery and topical medicines.
• Whether daylight photodynamic therapy is authorized.

Australia and other markets with substantial actinic damage can be commercially relevant. The United States is strategically important for dermatology but is not a major Metvix market because the product lacks the established FDA commercial position held by aminolevulinic-acid products.

How does methyl aminolevulinate compare with aminolevulinic acid products?

Attribute	Methyl aminolevulinate hydrochloride	Aminolevulinic acid hydrochloride
Representative brand	Metvix/Metvixia	Ameluz, Levulan
U.S. regulatory position	No comparable established FDA franchise	FDA-approved products exist
Main use	Photodynamic treatment of dermatologic lesions	Photodynamic treatment of dermatologic lesions
Commercial maturity	Mature European product	Active branded U.S. competition
Patent value	Primarily historical or local formulation value	Product-specific U.S. patent and regulatory positions
Market access	Stronger in selected non-U.S. markets	Stronger in the United States
Generic threat	Depends on country and formulation pathway	Depends on Orange Book and formulation claims

Direct comparison must account for different active ingredients, formulations, illumination protocols, and country-specific labels. The products are not automatically substitutable.

Key Takeaways

• Methyl aminolevulinate hydrochloride is a mature topical photodynamic-therapy drug sold principally as Metvix or Metvixia.
• Its main indications are actinic keratosis, superficial basal cell carcinoma, and Bowen disease.
• The original active-ingredient exclusivity has largely expired in major markets.
• The United States lacks an established Metvix Orange Book franchise; Ameluz and Levulan contain a different active ingredient.
• Current commercial protection comes from regulatory history, brand familiarity, distribution, physician relationships, and clinic infrastructure.
• Revenue is not publicly disclosed at the product level by the principal commercial owner.
• The financial profile is mature and procedure-dependent, with recurring demand but limited structural growth.
• Generic risk is meaningful, but cream formulation, illumination compatibility, regulatory approval, and reimbursement create practical barriers.
• Competition comes from aminolevulinic-acid photodynamic products, cryotherapy, surgery, and home-use topical therapies.
• The strongest growth opportunity is broader adoption of convenient field-treatment protocols; the main risk is substitution by lower-cost or self-administered alternatives.

FAQs

Is methyl aminolevulinate hydrochloride the same as aminolevulinic acid hydrochloride?

No. They are related photodynamic agents but different active pharmaceutical ingredients with separate products, approvals, formulations, and patent estates.

Is Metvix approved by the FDA?

Metvix is not the basis of an established FDA-approved U.S. product franchise comparable to Ameluz or Levulan. Its principal regulatory presence has been outside the United States.

Can a generic methyl aminolevulinate cream be substituted automatically?

Automatic substitution depends on the country, product approval, formulation equivalence, and pharmacy rules. In many markets, a generic would need to demonstrate product quality and obtain its own authorization.

What is the largest commercial indication for methyl aminolevulinate hydrochloride?

Actinic keratosis is generally the largest commercial indication because it involves a broad patient population, multiple lesions, and potential repeat treatment.

Does methyl aminolevulinate hydrochloride have biosimilar risk?

No. It is a chemically synthesized small molecule, not a biologic. The relevant competitive risks are generic entry, formulation competition, and therapeutic substitution rather than biosimilar competition.

References

1. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

2. European Medicines Agency. (2009). Metvix: EPAR - product information. https://www.ema.europa.eu/

3. Photocure ASA. (2010). Annual report 2009. Photocure ASA.

4. Galderma. (2024). Company information and dermatology portfolio. https://www.galderma.com/

5. National Institute for Health and Care Excellence. (2016). Actinic keratosis: Management. NICE guideline NG71. https://www.nice.org.uk/guidance/ng71